This comprehensive review emphasizes that a significant proportion of cancer cases are preventable through lifestyle modifications. The authors estimate that approximately 30–35% of cancer-related deaths are linked to dietary factors, 25–30% to tobacco use, 15–20% to infections, and the remainder to other factors such as physical inactivity, environmental pollutants, and
In her 1993 New York Times Magazine article, “Free Radicals: The Price We Pay For Breathing,” Natalie Angier delves into the paradox of oxygen metabolism: while essential for life, it inevitably leads to the production of free radicals—highly reactive molecules with unpaired electrons. These free radicals can damage cellular components
This 2017 review by Atilla Engin provides a comprehensive overview of the definitions and global prevalence of obesity and metabolic syndrome. Obesity is characterized by excessive fat accumulation that presents a risk to health, commonly assessed using body mass index (BMI). However, BMI does not account for fat distribution or
This 2009 systematic review and meta-analysis by Guh et al. evaluated the incidence of co-morbidities associated with overweight and obesity. The study analyzed 89 prospective cohort studies to estimate the relative risks (RRs) of various diseases in overweight and obese individuals compared to those with normal weight. Overweight (BMI 25–29.9
This 2017 review by Mattson, Longo, and Harvie, published in Ageing Research Reviews, examines the effects of intermittent fasting (IF) on health and disease processes in both animal models and humans. The authors discuss various IF regimens, including alternate-day fasting, the 5:2 diet, and time-restricted feeding, highlighting their potential benefits
This review explores the diverse biological effects of growth hormone-releasing hormone (GHRH) and its analogues, highlighting their potential therapeutic applications across various medical conditions. GHRH and its analogues stimulate cell growth, tissue repair, and wound healing, regulate apoptosis, modulate inflammation and immune responses, and offer neuroprotective effects, making them promising
This study compared the effectiveness of growth hormone-releasing hormone (GHRH(1-29)-NH₂) with standard growth hormone (GH) therapy in promoting growth in children with hypothalamic growth hormone deficiency (GHD). High-dose GHRH(1-29)-NH₂ significantly increased height velocity, comparable to GH treatment, but had no effect on bone age development. GHRH(1-29)-NH₂ did not induce GH
This study investigated the effects of dopaminergic, adrenergic, and cholinergic blockade, along with TRH administration, on growth hormone (GH) responses to growth hormone-releasing factor (GRF) 1-29. It was found that these neurotransmitter systems modulate GH secretion in response to GRF, and TRH administration also influenced GH release. The study highlights
This study explored the efficacy of intranasal growth hormone-releasing hormone (GHRH(1-29)-NH₂) in stimulating growth hormone secretion and improving growth in children with growth hormone deficiency. The results showed that intranasal GHRH(1-29)-NH₂ significantly increased GH secretion and improved linear growth, suggesting it could be a viable, non-invasive alternative to traditional GH
This study investigated the role of muscarinic cholinergic receptors in regulating growth hormone (GH) secretion in acromegalic patients. The trial involved eight subjects who received GH-releasing factor (GRF 1-29) and thyrotropin-releasing hormone (TRH) tests, with and without pirenzepine, a muscarinic antagonist. The results showed that muscarinic cholinergic blockade did not
